Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose study of intravenous SRK-001 in healthy volunteers
NL-OMON52159Phase 1Completed
- Sponsor
- Sarkana Pharma, Inc.
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3200327 in systemic lupus erythematosus (SLE) (5 arms), sponsored by Sarkana Pharma, Inc. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Nov 2021; status: completed.
02
Drugs
LY3200327
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON52159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52159.